A phase III randomized study of apremilast, an oral phosphodiesterase 4 inhibitor, for active ankylosing spondylitis by Taylor, P, van der Heijde, D, Landewé, R, McCue, S, Cheng, S, Boonen, A

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity by Landewé, R, Ritchlin, C, Aletaha, D, Zhang, Y, Ganz, F, Hojnik, M, Coates, L

Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort by Baraliakos, X, Pournara, E, Coates, LC, Navarro-Compán, V, Blanco, R, O’Brien, E, Schulz, B, Landewe, R

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study by Glatt, S, Taylor, P, McInnes, I, Schett, G, Landewe, R, Baeten, D, Ionescu, L, Strimenopoulou, F, Watling, M, Shaw, S

GOLIMUMAB IS EFFICACIOUS IN ANTI-TNF EXPERIENCED PTS WITH ACTIVE RA REGARDLESS OF TYPE OF AGENT OR REASON FOR DISCONTINUATION OF PRIOR ANTI-TNF: GO-AFTER STUDY by Smolen, J, Wordsworth, P, Doyle, M, Kay, J, Matteson, E, Landewe, R, Hsia, E, Zhou, Y, Rahman, M, Investigator, G

GOLIMUMAB, A HUMAN TNF-ALPHA mu ONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS PREVIOUSLY TREATED WITH ANTI-TNF-ALPHA AGENTS (GO-AFTER STUDY) by Wordsworth, P, Smolen, J, Kay, J, Doyle, M, Landewe, R, Matteson, E, Zhou, Y, Hsia, E, Rahman, M, Investigators, GO-AFTERS

GOLIMUMAB SIGNIFICANTLY IMPROVES PHYSICAL FUNCTION AND FATIGUE IN RA PATIENTS PREVIOUSLY TREATED WITH ANTI-TNF AGENTS: RESULTS FROM THE GO-AFTER STUDY by Kay, J, Wordsworth, P, Doyle, M, Smolen, J, Buchanan, J, Matteson, E, Hsia, E, Landewe, R, Zhou, Y, Shreekant, P, Rahman, M, Investigators, GO-AFTER

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active... by Ritchlin, CT, Coates, LC, McInnes, IB, Mease, PJ, Merola, JF, Tanaka, Y, Asahina, A, Gossec, L, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Landewé, R

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL) by McInnes, IB, Asahina, A, Coates, LC, Landewé, R, Merola, JF, Ritchlin, CT, Tanaka, Y, Gossec, L, Gottlieb, AB, Warren, RB, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J, Mease, PJ

EVALUATION OF EFFICACY AND SAFETY OF SECUKINUMAB IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ANKYLOSING SPONDYLITIS by Emery, P, Baeten, D, Sieper, J, Braun, J, van der Heijde, D, McInnes, I, Van Laar, J, Landewe, R, Wordsworth, B, Wollenhaupt, J, Kellner, H, Paramarta, I, Bertolino, A, Wright, A, Hueber, W

EARLY EFFECT OF SECUKINUMAB IN REDUCING SPINAL INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS by Van Laar, J, Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, Landewe, R, Wordsworth, B, Wollenhaupt, J, Kellner, H, Wright, A, Gsteiger, S, Hueber, W

Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Gsteiger, S, Hueber, W

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III... by Coates, LC, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gosse, L, Orbai, A-M, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Merola, JF

Bimekizumab in patients with active psoriatic arthritis and prior inadequate response or intolerance to tumour necrosis factor inhibitors: a randomised, double-blind, placebo-contr... by Merola, JF, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gossec, L, Gottlieb, AB, Thaçi, D, Warren, RB, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J, Coates, LC

Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions i... by Baeten, D, Bek, S, Wei, J, Brachat, A, Sieper, J, Emery, P, Braun, J, van der Heijde, D, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Paramarta, J, Bertolino, A, Wright, A, Wolfgang, H

LONG TERM INHIBITION OF IL-17A WITH SECUKINUMAB REDUCES SPINAL INFLAMMATION BUT HAS NO INFLUENCE ON FATTY LESIONS AS ASSESSED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOS... by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Hueber, W

Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Hueber, W

Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with... by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Wolfgang, H

Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. by Lassere, M, Johnson, K, Boers, M, Tugwell, P, Brooks, P, Simon, L, Strand, V, Conaghan, P, Ostergaard, M, Maksymowych, W, Landewe, R, Bresnihan, B, Tak, P, Wakefield, R, Mease, P, Bingham, C, Hughes, M, Altman, D, Buyse, M, Galbraith, S, Wells, G

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. by Baeten, D, Baraliakos, X, Braun, J, Sieper, J, Emery, P, van der Heijde, D, McInnes, I, van Laar, J, Landewé, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Paramarta, J, Wei, J, Brachat, A, Bek, S, Laurent, D, Li, Y, Wang, Y, Bertolino, A, Gsteiger, S, Wright, A, Hueber, W